Nanjing Leads Biolabs Co., Ltd. (HKG:9887)
Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
61.30
-1.90 (-3.01%)
Sep 10, 2026, 11:59 AM HKT

Nanjing Leads Biolabs Stock Forecast

Stock Price Forecast

According to 4 analysts polled by S&P Global, Nanjing Leads Biolabs stock has a consensus rating of "Buy" and an average price target of $103.15. The average 1-year stock price forecast is 68.27% higher than the current stock price, while the lowest is $85.13 (+38.87%) and the highest is $117.07 (+90.98%).

Price Target: $103.15 (+68.27%)
Analyst Consensus: Buy

Price Target

Chart
TargetLowAverageMedianHigh
Price$85.13$103.15$105.21$117.07
Change+38.87%+68.27%+71.63%+90.98%

Analyst Ratings

The average analyst rating for Nanjing Leads Biolabs stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Chart
RatingJan '26Mar '26Apr '26May '26Jul '26Aug '26
Strong Buy222222
Buy111111
Hold111111
Sell000000
Strong Sell000000
Total444444

Latest Forecasts

AnalystFirmRatingRatingActionPrice TargetUpsideDate
Unknown Analyst
SDIC Securities
No rating
SDIC Securities
Buy
Maintains
$83.34
BuyMaintains$83.34+35.95%Sep 4, 2026
CMB International Securities
CMB International Securities
Buy
Reiterates
$100.50
BuyReiterates$100.50+63.95%Sep 3, 2026
Unknown Analyst
Shenwan Hongyuan
No rating
Shenwan Hongyuan
Buy
Maintains
$108.89
BuyMaintains$108.89+77.63%Aug 22, 2026
Unknown Analyst
Morgan Stanley
No rating
Morgan Stanley
Hold
Maintains
$62.00$79.00
HoldMaintains$62.00$79.00+28.87%Jul 21, 2026
Unknown Analyst
CLSA
No rating
CLSA
Buy
Maintains
$108.00
BuyMaintains$108.00+76.18%Jul 13, 2026
More Analyst Ratings

Financial Forecast

Revenue This Year
277.84M
from 177.26M
Increased by 56.75%
Revenue Next Year
579.97M
from 277.84M
Increased by 108.74%
EPS This Year
-0.95
from -1.03
EPS Next Year
-0.73
from -0.95
Fiscal YearFY 2023FY 2024FY 2025FY 2026
Period EndingDec 31, 2023Dec 31, 2024Dec 31, 2025Dec 31, 2026
Revenue
8.87M-177.26M277.84M
Revenue Growth
---56.75%
Gross Profit
5.68M-177.26M276.31M
Gross Margin
64.07%-100.00%99.45%
Operating Income
-263.23M-273.38M-194.53M-217.84M
Net Income
-362.25M-301.22M-211.42M-208.78M
EPS
---1.03-0.95
Free Cash Flow
--1.34B-92.39M-267.57M
No. Analysts
---4
EPS and Forward PE are based on non-GAAP adjusted numbers. Financial currency is CNY.

Revenue Forecast

Revenue202620272028
High322.0M
Avg277.8M
Low248.2M

Revenue Growth

Revenue Growth202620272028
High
81.7%
Avg
56.7%
Low
40.0%

EPS Forecast

EPS202620272028
High-0.76
Avg-0.95
Low-1.14

EPS Growth

EPS Growth202620272028
High-
Avg-
Low-